Navigation Links
Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors
Date:12/5/2007

BOULDER, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) today announced the appointment of Eric K. Rowinsky, M.D., and Martin Cannon to the Company's Board of Directors. Dr. Rowinsky is Senior Vice President and Chief Medical Officer for ImClone Systems, Inc. Mr. Cannon is the President and Chief Executive Officer for New Health Sciences, Inc.

The Company also announced that Arthur Hayes, Jr., M.D. has resigned from Tapestry's Board after eleven years of service. Dr. Hayes informed the Company that his resignation is due to other fiduciary obligations which might potentially interfere with his duties as a Tapestry director.

"We welcome the wealth of oncology drug development and business management experience that Dr. Eric Rowinsky and Martin Cannon are bringing to our board," commented Leonard Shaykin, Chairman and Chief Executive Officer. "We also wish Dr. Hayes the very best in his future endeavors. Arthur is a dear friend of the Company and a man of great integrity; we will miss his counsel."

Dr. Rowinsky is Senior Vice President and Chief Medical Officer for ImClone Systems, Inc. where he is focusing exclusively on the development of novel cancer therapeutics. Previously Dr. Rowinsky served as Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio and the SBC Endowed Chair for Early Drug Development. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio. Prior to that, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine. He was a longstanding National Cancer Institute principal investigator, integrally involved in pivotal clinical and preclinical investigations which led to the development of both classical chemotherapeutics and targeted therapies including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, and gefitinib, among others. Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and/or Editorial Board Member of Cancer Research, Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published over 270 manuscripts in both the preclinical and clinical research fields. Dr. Rowinsky's honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He also served on the Board of Scientific Counselors of the NCI.

Martin Cannon, prior to his appointment as President and Chief Executive Officer of New Health Sciences, Inc., a company developing technology for diagnosis and management of neuro-degenerative diseases, was Executive Vice President at Commerce One, where he was responsible for all business consulting divisions and all of the company's E-Commerce exchanges. He was also founder of Cannon Associates, a consulting firm focused on high growth opportunities in new technologies and emerging markets, including extensive work in clinical diagnostics and therapeutics in the US and internationally. Previously he was a Partner at the management consulting firms AT Kearney and Bain and Company, leading major multiyear growth and profit improvement programs for numerous Fortune 500 companies in healthcare and life sciences.

Dr. Arthur Hayes commented: "I have enjoyed my tenure on Tapestry's Board and continue to believe strongly in the Company. From this point on I will be cheering from the sidelines."

About Tapestry Pharmaceuticals, Inc.

Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. Tapestry's lead candidate, TPI 287 is in multiple Phase 2 clinical studies at this time.

For more information about Tapestry and its technologies, visit Tapestry's website at http://www.tapestrypharma.com.

Contact:

Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor: Lilian Stern

Stern Investor Relations, Inc.

212-362-1200

lilian@sternir.com

Media: Dana Conti

Schwartz Communications

781-684-0770

tapestry@schwartz-pr.com


'/>"/>
SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Purple: The Hottest Color for Fall in Shoes, Handbags and Martinis
2. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
3. WellPoint Announces Appointment of John Cannon III as Executive Vice President & General Counsel
4. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Richard Greco Joins Mediware Board
8. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
9. Accident Fund Will Make Board of Water & Lights Ottawa Street Station Power Plant in Lansing Its New National Headquarters
10. Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers
11. Montana Health Care Leader Elected Board Chair of National Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg ... life. Although frozen embryos have a slight statistical advantage for live births, frozen ... a wonderful opportunity for women undergoing medical treatment or who are concerned about ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for ... 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device ... of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... 21, 2017 , ... Innovatum will demonstrate capabilities of fully ... Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses ... patient safety. , Microscan , a global technology leader in barcoding, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: